Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NYMXF Alzheimer's treatment! -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (113)	7/30/1998 3:28:00 PM
From: Demetre Deliyanakis	Respond to of 132

What were the revenues reported from service fees in the second quarter ? When will the urinary test be made available. The press release is vague. When will human clinical trials of nx-d2858, the lead drug candidate begin?. The cash on hand will pay for approximately 1 year of work at current levels. The company will need more financing if it expects to be able to market the test effectively. I hope that they find a partner with deep pockets soon. The stock has fallen sharply in the past few weeks. I am not sure if today's announcement will push the stock back up to the $10 range.

To: Ron who wrote (113)	8/5/1998 8:13:00 AM
From: Demetre Deliyanakis	Read Replies (1) \| Respond to of 132

The press release by Nymox on July 31 is discouraging. The company decided not to proceed with an equity offering due to the low value of their shares. On the one hand, you could make a case that to issue more shares at the present time would dilute earnings. However, I think that Nymox will need more financing within a year if it wants to continue its research and development. An additional equity offering would also help attract more analyst coverage. According to the Globe and Mail, the earnings released by Nymox showed that there was no revenue during the second quarter. This is disturbing considering the publicity that the company attracted during March and April. Is Nymox is giving away the test ?. If so, why doesn't the company publish the number of tests that it has given away.? This would be helpful to determine how the test is being received in the medical community.